Evidence map›Paper›PMID 40170468›Full record

ArticleDrug delivery2025

Orchestrating T and NK cells for tumor immunotherapy via NKG2A-targeted delivery of a de novo designed IL-2Rβγ agonist.

Jie Chen, Enhui Ren, Ze Tao, Hongyu Lu, Yunchuan Huang, Jing Li, Yuzhe Chen, Zhuo Chen, Tianshan She, Hao Yang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jie ChenDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Enhui RenDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Ze TaoDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Hongyu LuDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Yunchuan HuangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Jing LiDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Yuzhe ChenDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Zhuo ChenDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Tianshan SheDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Hao YangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Hong ZhuDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xiaofeng LuDivision of Abdominal Tumor Multimodality Treatment, Cancer Center; NHC Key Lab of Transplant Engineering and Immunology, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As T and NK cell exhaustion is attributed to increased expression of immune checkpoints and decreased production of proliferative cytokines by these cells, immune checkpoint-targeted delivery of proliferative cytokines might induce robust and sustained antitumor immune responses. Here, the expression profile of NKG2A was first found to be narrower than that of PD-1 in tumor-infiltrated immune cells. Moreover, unlike PD-1, NKG2A was predominantly co-expressed with IL-2Rβγ in tumor-infiltrated CD8

Indexed as

ImmunotherapyInterleukin-2 Receptor beta SubunitKiller Cells, NaturalNeoplasmsNK Cell Lectin-Like Receptor Subfamily CAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceMice, Inbred C57BLInterleukin-2 Receptor beta SubunitNK Cell Lectin-Like Receptor Subfamily CIgG-binding domainIL-2R agonistimmune checkpoint inhibitorImmunotherapyT and NK cell exhaustion

Identifiers

PMID40170468
PMCPMC11966987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.